Sight SciencesSGHT +4.50%71 Days Payable is 47.45 as of Mar. 2026, which is 47% below its 10-year median of 88.90. GuruFocus rates SGHT with a GF Score™ of 71/100 and a GF Value™ of $4.49 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Sight Sciences ranks worse than 55.6% on this metric.
The historical rank and industry rank for Sight Sciences's Days Payable or its related term are showing as below:
SGHT'
s Days Payable Range Over the Past 10 Years
Min: 51.76 Med: 88.9 Max: 293.34
Current: 62.44
During the past 8 years, Sight Sciences's highest Days Payable was 293.34. The lowest was 51.76. And the median was 88.90.
SGHT's Days Payable is ranked worse than 55.6% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 67.87
vs SGHT: 62.44
Sight Sciences's Days Payable
declined
from Mar. 2025 (84.22) to Mar. 2026 (47.45).
It may suggest that Sight Sciencesaccelerated paying its suppliers.
Sight Sciences Days Payable Related Terms
Sight Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for Sight Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Sight Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sight Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sight Sciences (SGHT) has a Days Payable of 47.45 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sight Sciences and its competitors. This is 47% below median its historical median of 88.90. Over the past decade, Sight Sciences' Days Payable has ranged from 51.76 to 293.34. According to the industry distribution chart, Sight Sciences ranks #442 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 55.6%.
Is Sight Sciences' Days Payable too high?
Sight Sciences' current Days Payable of 47.45 is 47% below median its 10-year median of 88.90. Over the past 10 years, this metric has ranged from a low of 51.76 to a high of 293.34. The Medical Devices & Instruments industry median Days Payable is 67.87. Sight Sciences' value of 47.45 is 30.1% below this industry median. Based on the distribution chart, Sight Sciences ranks #442 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sight Sciences has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Days Payable compare to QSI and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #442 out of 795 companies for Days Payable. This places Sight Sciences in the lower half of its industry. The industry median Days Payable is 67.87. Sight Sciences' value of 47.45 is 30.1% below this benchmark. Historically, Sight Sciences' own Days Payable has ranged from 51.76 to 293.34 over the past decade. While the company's 10-year median is 88.90 vs. the industry median of 67.87, Sight Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.87, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current Days Payable of 47.45 is 30.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current Days Payable is 47.45, which is 47% below median its own 10-year median of 88.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $5.67 — trading 26.3% above its estimated fair value. The current Days Payable is 47.45, which is 47% below median its 10-year median of 88.90 and 30.1% below the Medical Devices & Instruments industry median of 67.87. Sight Sciences' overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Days Payable is 47.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.67 is trading 26.3% above its estimated GF Value™ of $4.49.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
Days Payable: 47.45 (47% below median its 10-year median of 88.90)
GF Value™: $4.49 vs. price of $5.67 (26.3% above fair value)
Industry Position: 30.1% below the Medical Devices & Instruments median (#442 of 795)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
71GF Score
Get the complete analysis for SGHT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
